Pfizer’s stock falls after mixed response to weight-loss data for drug set to compete with Lilly’s Zepbound

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration’s policies on pricing and tariffs.